Text and Data Mining valid from 2018-09-01
Received: 8 May 2018
Revised: 30 July 2018
Accepted: 10 August 2018
First Online: 17 September 2018
<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate:
: Tumour analysis was performed as part of the TARGET study, and was approved by the Sydney Children’s Hospital Network Human Research Ethics Committee in accordance with the Declaration of Helsinki.
: Consent was provided by the parents for publication of this case.
: M.R. is a consultant for Loxo Oncology, Inc and holds a patent 62/318,041 issued to Loxo Oncology, Inc. M.C.C. is an employee of and owns stock in Loxo Oncology, Inc and holds a patent 62/318,041 issued to Loxo Oncology, Inc. The remaining authors declare no competing interests.
: All data generated or analysed during this study are included in this published article.
: The brain tumour precision medicine program was funded by the Cure Brain Cancer Foundation. Whole-Genome Sequencing was funded by the Australian Lions Childhood Cancer Research Foundation and Lions Club International Foundation (LCIF) as part of the Lions Kids Cancer Genome Project. AK and VT’s salaries were supported by the CRC for Cancer Therapeutics, EM’s salary was supported by The Kids Cancer Project, LL’s and CM’s salary were supported by Cancer Institute NSW, and MJC’s salary was supported by NSW Department of Health Early-Mid Career Fellowship. DK is the Herman Clinical Fellow at the University of Melbourne. The Zero Childhood Cancer Program has also been supported by the Commonwealth Government of Australia, The NSW State Government, University of NSW, Tour de Cure, The Rich Family Foundation, the Robert Connor Dawes Foundation, and The Lenity Foundation.